Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join


Mar 22, 2021 9:50 AM - Mar 24, 2021 2:30 PM

(Eastern Standard Time)

Medical Affairs and Scientific Communications Forum

Session 8 Track 3: Why Science Needs More Diversity in Clinical Trials

Session Chair(s)

Lori  Mouser, PharmD

Lori Mouser, PharmD

Senior Director, Global Head of Oncology Scientific Engagement and Congresses

Daiichi Sankyo Inc., Switzerland

This session will focus on the scientific rationale for driving for more diversity in clinical trial programs. Ideas for how to ensure more diverse populations of patients have access to clinical trials as an option to treatment will be shared. Presenters will explore the role field teams can play in engaging with clinical trial sites.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify examples of where race or gender differences lead to divergent clinical outcomes.
  • Discuss reasons why broadening the diversity of patients across clinical trial programs is needed.
  • Describe how field medical teams can support clinical trial sites in patient screening and enrollment.


Danielle  Day, PhD


Danielle Day, PhD

Sobi, United States

Senior Medical Director, Immunology, Rare Disease

Nicole  Richie, PhD


Nicole Richie, PhD

Genentech, United States

Global Head Health Equity and Population Science, Clinical Development

Bethsheba  Johnson


Bethsheba Johnson

Gilead Sciences, Inc, United States

Senior Director, HIV Prevention Field Director Western US

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.